Sec Form 4 Filing - Brennan Peter F @ CALMARE THERAPEUTICS Inc - 2018-02-12

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Brennan Peter F 2. Issuer Name and Ticker or Trading Symbol CALMARE THERAPEUTICS Inc [ CTTC] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X __ Director _____ 10% Owner _____ Officer (give title below) _____ Other (specify below) (Last) (First) (Middle) 1375 KINGS HIGHWAY EAST 3. Date of Earliest Transaction (MM/DD/YY) 02/12/2018 (Street) FAIRFIELD, CT06824 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 02/12/2018 M 4,594,117 A 13,850,181 D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Warrant $ 0.6 02/12/2018 C 123,530 ( 1 ) ( 1 ) Common Stock 123,530 $ 0.6 123,530 D Warrant $ 0.6 02/12/2018 C 411,765 ( 2 ) ( 2 ) Common Stock 411,765 $ 0.6 535,295 D Warrant $ 0.13 02/12/2018 C 764,706 ( 3 ) ( 3 ) Common Stock 764,706 $ 0.13 1,300,001 D Warrant $ 0.13 02/12/2018 C 1,882,362 ( 4 ) ( 4 ) Common Stock 1,882,362 $ 0.13 3,182,353 D Warrant $ 0.125 02/12/2018 C 1,411,765 ( 5 ) ( 5 ) Common Stock 1,411,765 $ 0.125 4,594,117 D

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Brennan Peter F 1375 KINGS HIGHWAY EAST FAIRFIELD, CT06824 X Signatures /s/ Peter Brennan 03/06/2018 Signature of Reporting Person Date

Explanation of Responses:

( 1 )The Reporting Person received a warrant to purchase 123,530 shares of Common Stock on 02/23/2017 inconnection with a Note Purchase Agreement executed on that date. The exercise price was $0.60 per share. The warrant was exercisable immediately and expired in one year-02/23/2018. ( 2 )The Reporting Person received a warrant to purchase 411,765 shares of Common Stock on 05/16/2017 in connection with a Note Purchase Agreement executed on that date. The exercise price was $0.60 per share. The warrant was exercisable immediately and expired in one year-05/16/2018. ( 3 )The Reporting Person received a warrant to purchase 764,706 shares of Common Stock on 07/24/2017 in connection with a Note Purchase Agreement executed on that date. The exercise price was $0.13 per share. The warrant was exercisable immediately and expired in one year - 07/24/2018. ( 4 )The Reporting Person received a warrant to purchase 1,882,352 shares of Common Stock on 12/29/2017 in connection with a Note Purchase Agreement executed on that date. The exercise price was $0.13 per share. The warrant was exercisable immediately and expired in one year-12/29/2018. ( 5 )The Reporting Person received a warrant to purchase 1,411,765 shares of Common Stock on 02/01/2018 in connection with a Note Purchase Agreement executed on that date. The exercise price was $0.125 per share. The warrant was exercisable immediately and expired in one year- 02/01/2019.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.